Medexus Pharmaceuticals Inc. (TSX:MDP)
Canada · Delayed Price · Currency is CAD | Market Cap | 127.14M +45.4% |
| Revenue (ttm) | 136.34M -9.2% |
| Net Income | -372.95K |
| EPS | -0.01 |
| Shares Out | 32.03M |
| PE Ratio | n/a |
| Forward PE | 9.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,112 |
| Average Volume | 42,135 |
| Open | 3.970 |
| Previous Close | 3.920 |
| Day's Range | 3.880 - 3.990 |
| 52-Week Range | 2.470 - 4.160 |
| Beta | 1.82 |
| RSI | 54.62 |
| Earnings Date | Jun 24, 2026 |
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medicatio... [Read more]
Full Company ProfileNews
Medexus Pharmaceuticals Transcript: 16th Annual LD Micro Invitational Conference
Revenue and EBITDA remain stable, with growth now driven by GRAFAPEX, an orphan drug for AML and MDS showing strong early adoption and clinical outcomes. The company is focused on expanding its rare disease portfolio through accretive acquisitions and expects to more than double revenue in the coming years.
Medexus Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
A diversified pharma portfolio is driving steady revenue and EBITDA, with GRAFAPEX poised to double revenue at high margins. Strong hospital uptake, favorable reimbursement, and robust clinical data support U.S. peak sales of $100–$175 million within 3–5 years.
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercializa...
Medexus Pharmaceuticals Earnings Call Transcript: Q3 2026
Fiscal Q3 2026 saw net revenue of $25.3M and adjusted EBITDA of $4.5M, with GRAFAPEX driving growth and expected to be accretive to cash flows in Q4. Gross margin improved to 53.6%, and a new credit facility enhanced financial flexibility.
Medexus Pharmaceuticals Earnings release: Q3 2026
Medexus Pharmaceuticals released its Q3 2026 earnings on February 12, 2026, summarizing the period's financial results.
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Thursday, February 12, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: M...
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Feb...
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Med...
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National ...
Medexus Pharmaceuticals Earnings Call Transcript: Q2 2026
Graphopex outperformed expectations, driving strong adoption and positive feedback, with guidance for continued revenue growth and positive cash flow in fiscal Q3 2026. Portfolio performance was mixed, with generic competition impacting some products and gross margin improving year-over-year.
Medexus Pharmaceuticals Earnings release: Q2 2026
Medexus Pharmaceuticals released its Q2 2026 earnings on November 13, 2025, summarizing the period's financial results.
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Thursday, November 13, 2025 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: M...
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Nov...
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareho...
Medexus Pharmaceuticals Transcript: AGM 2025
Shareholders reviewed financial statements, elected seven directors, and reappointed PwC as auditor, with all proposals approved. No questions were raised, and voting was conducted online. Forward-looking risks were referenced in regulatory filings.
Medexus Pharmaceuticals Transcript: Canaccord Genuity’s 45th Annual Growth Conference
A diversified rare disease-focused pharma is accelerating growth with the U.S. launch of GRAFAPEX, which is expected to more than double revenue and drive higher margins. The company leverages efficient M&A, a strong commercial platform, and is actively seeking late-stage assets for future expansion.
Medexus Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw strong early GRAFAPEX adoption, offsetting declines from portfolio maturity and generic competition, with $24.6M revenue and improved gross margin. GRAFAPEX is expected to drive future growth, supported by NTAP reimbursement and robust business development prospects.
Medexus Pharmaceuticals Earnings release: Q1 2026
Medexus Pharmaceuticals released its Q1 2026 earnings on August 13, 2025, summarizing the period's financial results.
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million $3.0 million of product-level net revenue from GRAFAPEX ...
Medexus Schedules First Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, Augu...
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Service...
Medexus Pharmaceuticals Earnings Call Transcript: Q4 2025
GRAFAPEX's U.S. launch drove strong early revenue and positive market response, with expectations for continued sequential growth and accretive contribution by fiscal Q4 2026. Fiscal 2025 saw record adjusted EBITDA and net income, while base franchises are expected to remain stable or slightly decline.
Medexus Pharmaceuticals Earnings release: Q4 2025
Medexus Pharmaceuticals released its Q4 2025 earnings on June 26, 2025, summarizing the period's financial results.
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 million US commercial launch of GRAFAPEX™ executed...
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 2...